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Abstract: Accurate prevalence data are essential for the elimination of lymphatic filariasis (LF)
as a public health problem. Despite it bearing one of the highest burdens of disease globally,
there remains limited reliable information on the current epidemiology of filariasis in mainland
Southeast Asia. We conducted a systematic review and meta-analysis of available literature to assess
the recent and current prevalence of infection and morbidity in the region. Fifty-seven journal
articles and reports containing original prevalence data were identified, including over 512,010
participants. Data were summarised using percentage prevalence estimates and a subset combined
using a random effects meta-analysis by country and year. Pooled estimates for microfilaraemia,
immunochromatographic card positivity and combined morbidity were 2.64%, 4.48% and 1.34%
respectively. Taking into account pooled country estimates, grey literature and the quality of available
data, we conclude that Lao People's Democratic Republic (PDR), Myanmar and Northeast India
demonstrate ongoing evidence of LF transmission that will require multiple further rounds of mass
drug administration. Bangladesh, Malaysia, Thailand and Vietnam appear close to having eliminated
LF, whilst Cambodia has already achieved elimination status. We estimate that the burden of
morbidity is likely high in Thailand; moderate in Cambodia, Myanmar, and Northeast India; and low
in Bangladesh. There was insufficient evidence to accurately estimate the disease burden in Lao PDR,
Malaysia or Vietnam. The results of this study indicate that whilst considerable progress toward LF
elimination has been made, there remains a significant filariasis burden in the region. The results of
this study will assist policy makers to advocate and budget for future control programs.
Keywords: lymphatic filariasis; Southeast Asia; prevalence; infection; morbidity; lymphoedema;
hydrocoele
1. Introduction
Lymphatic filariasis (LF) is a mosquito-borne tropical disease that affects 67.88 million people in
73 countries worldwide [1–3]. It is caused by infection with the nematodes Wuchereria bancrofti (Wb),
Brugia malayi (Bm) or Brugia timori. Chronic infection causes lymphatic dysfunction, resulting in severe
morbidity from progressive, irreversible swelling of the limbs and genitals. LF is a significant cause of
permanent disability worldwide, accounting for an estimated 19.43 million cases of hydrocoele, 16.68
million cases of lymphoedema and 2.02 million disability-adjusted life years lost [3,4].
In recognition of the significant worldwide burden of LF, the World Health Organization
(WHO) established the Global Program to Eliminate LF (GPELF) calling for the elimination of LF
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by 2020 [1,5]. The program adopted a two-pronged approach: first, interrupt transmission through
annual single-dose mass drug administration (MDA) of entire at-risk populations with albendazole in
combination with either diethylcarbamazine (DEC) or ivermectin for a minimum of five years; and,
second, alleviate the significant morbidity burden associated with the disease.
Numerous methods are currently used to diagnose LF infection. Traditionally, thick blood smears
(TBS) were used to identify microfilaraemia (mf) in the peripheral circulation. TBS have now been
largely superseded by more sensitive antigen-based tests but are still used as a measure of potential
infectivity and ongoing transmission. Antigen tests include immunochromatographic card tests (ICT)
and Og4C3 enzyme-linked immunosorbent assays (ELISA) which use monoclonal antibodies to detect
the excretory-secretory antigens produced by adult filarial worm infection [6,7]. Because they detect a
different stage of the life-cycle and do not require adult worms to be producing microfilariae, they are
two- to fivefold more sensitive than TBS [8]. Antibody-based tests detect circulating IgG4 antibodies
against Bm14 antigen (B. malayi and W. bancrofti) or BmR1 (B. malayi only) [9]. Whilst highly sensitive
and specific, antibody prevalence cannot prove current infection because antibodies remain elevated
for many years after treatment [9]. Urinary antibody tests have been trialled but are less sensitive than
blood-based antibody tests [8,10]. PCR assays to detect LF DNA in humans are also available, but are
not used routinely because they require advanced laboratory facilities and are less sensitive than other
methods [8,10].
LF is endemic in all countries within mainland Southeast Asia [1,2,5]. The geographical region
spans both the WHO Southeast Asia and Western Pacific regions and includes Cambodia, Lao People’s
Democratic Republic (PDR), Myanmar, Thailand, Vietnam and Malaysia. Emerging data suggest
a possibly high prevalence of filariasis in Myanmar. Given the country’s significant shared border with
Northeast India and Bangladesh, both were also included.
The WHO Southeast Asia and Western Pacific regions account for 55.7% of the at-risk population,
with 94.6% of reported lymphoedema cases and 85.2% of reported hydrocoele cases globally [2].
The areas considered here (mainland Southeast Asia plus Northeast India and Bangladesh) account for
over a fifth of the population of these two regions. Elimination of LF in this area would therefore have
a significant impact on the global disease burden. LF in these countries is caused by W. Bancrofti and
B. malayi, and transmitted mainly by Culex quinquefasciatus, with some contribution by Aedes spp. and
Mansonia spp. mosquitoes [11].
All countries in this review have commenced elimination programs. Elimination as a public
health problem has been validated in Cambodia, whilst Bangladesh, Thailand and Vietnam have
transitioned to post-MDA surveillance. The remaining countries are still conducting MDA [1,2,5].
WHO country validation of ‘elimination of LF as a public health problem’ requires a set of surveys
and steps to determine whether the prevalence is below the target level (upper 95% CI of 2% in Culex
spp. transmission areas such as Southeast Asia) [12]. One important milestone is the passing of three
consecutive transmission assessment surveys (TAS) conducted on six- to seven-year-old children in
each defined geographical evaluation unit (EU). The TAS survey sets critical cut-off values for the
number of positive children that must not be exceeded for the EU to pass [13]. The sample sizes and
critical cut-off values for the TAS in Culex spp. transmission areas are designed so that an EU has (1) at
least a 75% chance of passing if the true prevalence of antigenaemia is 1.0% (half the target level); and
(2) no more than a 5% chance of incorrectly passing if the true prevalence of antigenaemia is ≥2% [13].
Despite the significant LF burden in this region, there remain limited reliable data on the current
prevalence of infection and morbidity. Whilst previous reviews have examined this topic, all are
significantly out-dated or incomplete [14–16]. Reliable, current data on the prevalence of LF are
required for the implementation and evaluation of elimination programs as well as future advocacy
efforts. Accordingly, we conducted a systematic review and meta-analysis of publicly-available data
in studies and grey literature to assess the recent (since the early 1990s) and current prevalence of LF
infection and morbidity in mainland Southeast Asia, Bangladesh and Northeast India.
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2. Materials and Methods
2.1. Protocol
This systematic review is reported using the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) guidelines [17]. A review protocol was registered with PROSPERO
international prospective register of systematic reviews, which can be viewed online [18].
2.2. Information Sources
Information was gathered through three sources: (1) a literature search of PubMed and MEDLINE
databases; (2) a web-based search of the WHO library for relevant publications; and (3) direct contact
with regional and national LF Program directors to obtain National LF Program reports [19]. Countries
with National LF Programs submit annual reports to their respective WHO regional office outlining
their MDA and surveying activities for the preceding year. A summary of the data is published
annually in a regional WHO meeting report. Reference lists of all papers were screened to identify
additional publications.
2.3. Search Strategy
A literature search was conducted for available publications on PubMed and MEDLINE via
OvidSP up until 11 December 2016 by one investigator. The search strategy used for both databases
was: (lymphatic filariasis or Wuchereria bancrofti or Brugia timori or Brugia malayi or lymphoedema
or hydrocoele or elephantiasis or microfilariae or microfilaraemia) AND ((Myanmar or Burma or
Thailand or Laos or Cambodia or Vietnam or Malaysia or Bangladesh) OR (India and Assam or
Meghalaya or Nagaland or Manipur or Tripura or Mizoram or Arunachal Pradesh)). Combinations of
the database search terms were used to search the WHO library.
2.4. Study Selection and Inclusion Criteria
The titles, abstracts and if indicated, full text of records from online databases and the WHO
library (IRIS) were screened for eligibility. Published studies and reports with original prevalence
data on LF infection or morbidity from identified countries were included. Where reports were not
available, WHO publications referencing their data were used and recorded.
Only literature available in English and published from 1995 onward was included. There were
no restrictions on age, study size, design or power. Any uncertainty regarding the inclusion of a paper
was resolved through consensus discussion with other authors.
2.5. Data Collection Process
A standardised data collection form was used to record information from included publications.
All data was then entered into a Microsoft Excel spreadsheet for analysis.
2.6. Data Items
Extracted data included study characteristics, sampling method and prevalence data. Data were
extracted directly from text and tables within the publications.
Primary outcomes were the prevalence of infection (including measurement method and species)
and chronic morbidity (lymphoedema or hydrocoele) in the given population.
Where interventional studies were included, the prevalence data that were most representative of
the population were used. That is, when a whole area participated in MDA external to the study, the
post-intervention data were used. When an intervention was implemented only on the study sample,
baseline data were used.
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2.7. Risk of Bias Assessment
A modified bias risk assessment tool was developed to evaluate included studies. It was based
on the Crowe and GATE validated critical appraisal tools [20,21]. Risk of bias was assessed by one
reviewer on the basis of five independent factors: total sample size (>1000, 300–1000 or <300), sampling
of location (representative randomisation, not stated/unclear or non-representative), sampling of
participants (representative randomisation, not stated/unclear or non-representative), assessment of
infection (internationally accepted methodology, not stated/unclear or non-consensus methods) and
assessment of morbidity (independently assessed, not stated/unclear or patient reported). A total
risk of bias score was generated by allocating zero, one or two points for each factor. The quality
assessment was used to interpret the reliability of each study’s results. Because of the limited number
and significant quality variation between studies, the bias assessment was not incorporated directly
into the meta-analysis.
WHO filariasis publications are based on national LF programs annual reports. WHO Regional
Program Review Groups (RPRG) assess annual national LF program surveillance reports during their
consideration of the country’s request for the donation of MDA drugs. Although general guidelines
are provided by WHO, methodology within countries frequently varies substantially and may not
be optimal due to poorly resourced programs and frequent personnel changes [22]. Independent
assessments of data quality within programs are rarely done.
2.8. Summary Measures and Synthesis of Results
Available data were summarised using percentage prevalence estimates and presented in tables
by country and region.
A meta-analysis of primary outcomes from studies was completed using the metaprop procedure
in STATA version 12.1 to produce overall estimates with exact binomial confidence intervals. A subset
meta-analysis of migrant workers in Thailand and India was also done. A random effects model was
used to account for the variation in LF prevalence between and within studies.Weighting of studies
was done using the method of DerSimonian and Laird [23]. The heterogeneity of data from each
meta-analysis was measured using the I2 statistic [24].
A map of baseline and most recent LF distribution was generated by combining government
prevalence maps found in grey literature. Endemicity was classified at implementation unit level by
all countries. Recent maps were available for all countries except Malaysia.
3. Results
3.1. Study Selection
The search protocol identified 629 papers (Figure 1). Of these, 554 clearly did not meet the
inclusion criteria (i.e., were review articles or did not include original prevalence data on infection
or morbidity published since 1995 from the identified areas). From the remaining 75 records, 17
were excluded because they did not contain original prevalence data, and one because the full text
was not available after contacting the author. The included 57 papers comprised 38 peer-reviewed
journal articles and 19 grey literature reports [5,25–79]. With the exception of Chansiri et al. [30],
which contained only polymerase-chain reaction (PCR) infection data, all studies were included in
the meta-analysis.
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Figure 1. Study selection flow chart.
3.2. Study Characteristics
The characteristics of the 38 included journal articles are summarised by country in Table 1.
This includes 17 from Thailand, eight each from Malaysia and Northeast India, three from Bangladesh
and two from Cambodia. There were no studies included from Lao PDR, Myanmar or Vietnam.
All articles described primary studies, and included cross-sectional surveys (CSS) (25 studies,
66%), field diagnostic test evaluation studies (FDE) (8, 21%), field drug trials (FDT) (3, 8%) as well
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as a longitudinal observational and a retrospective cohort study. Publication year ranged from 1995
to 2016.
Together the included studies assessed 382,274 participants with wide variation in sampling
unit and sample size (145 to 232,005). Two studies, Saha et al. (2011) and Krairittichai et al. (2012),
contributed substantially to overall participant numbers with sample sizes of 232,005 and 102,090,
respectively [44,55]. Eleven of the 17 studies from Thailand assessed Myanmar migrant populations,
whilst seven of the eight papers from Northeast India examined those living in tea estates.
Studies most frequently assessed infection with the traditional thick blood smear (TBS) method
(30 studies, 79%), followed by ICT (10, 26%), IgG4 antibody (10, 26%), Og4C3 ELISA (6, 16%) and PCR
(3, 8%) tests. One study used urine rather than blood to detect IgG4 antibodies [56]. Almost half of
the studies (16, 42%) used multiple methods. Sixteen studies assessed the prevalence of chronic LF
morbidity. Of these, seven (44%) assessed both hydrocoele and lymphoedema.
Table 2 summarises the characteristics of the 19 included grey literature reports. These include 15
WHO publications, three annual national programmatic reports and a report from a non-governmental
organisation.With the exception of one WHO report, all papers summarise data from government
prevalence surveys conducted as part of their national MDA programs. Whilst only some sample sizes
were reported, at least 129,736 individuals were surveyed. Baseline mapping and MDA surveillance
surveys predominantly used TBS to diagnose infection, whilst post-MDA TASs used ICT.Some
government morbidity information was available for all countries, but the data were very limited.
3.3. Risk of Bias within Studies
The risk of bias assessment of included studies is summarised in Table S1. Overall, study quality
was suboptimal. Only seven studies (18%) used fully representative sampling methods and consensus
data collection methods.
The sample sizes of published studies were overall acceptable, with 33 studies including greater
than 300 participants. However, sample sizes were generally small relative to government surveys.
The sampling of study location introduced a significant risk of bias. Only ten (26%) studies
adequately described the random site selection required for regionally representative data. Of the
remaining studies, 21 (55%) did not describe the method/reason for study site selection, and seven
(18%) intentionally selected study sites.
Participant sampling within study locations also contributed to risk of bias. Only 18 (47%) studies
described random participant selection. Eighteen (47%) studies did not clearly state the method of
selection, whilst the remaining two studies excluded those with recent diethylcarbamazine treatment.
With the exception of Chansiri et al., all studies used a consensus method for the detection of LF
infection [30]. It is unclear whether the TBS samples in Krairittichai et al. were taken at night, which
may have affected the sensitivity of their results [44].
Of the fifteen studies that assessed LF morbidity, only four (25%) described examination methods
in detail. Of the remaining papers, eight (50%) provided some detail and four (25%) did not state the
method used.
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Table 1. Included peer-reviewed journal articles.
Study (Publication Date) [Study Period] [Ref.] Study Design Sampling Population/Unit (Age of Participants) Sample Size
Diagnostic Method
Infection Morbidity
Bangladesh
Hafiz et al. (2015) (2011) [33] CSS b Households in 30 villages (≥10) 1242 Mf, ICT Hyd./Lymph. h
Saha et al. (2011) [NS g] [55] CSS Households in 19 unions (≥1) 232,005 - Lymph.
Samad et al. (2013) [NS] [56] FDE a School children (5–10) 319 ICT, IgG4 e -
Cambodia
Leang et al. (2004) (2000–2001) [45] CSS 83 villages (≥1) 3468 Mf, ICT Hyd./Lymph.
Priest et al. (2016) (2012) [52] CSS 2200 households (women 15–39) 2150 IgG4 -
Northeast India
Dutta et al. (1995) (1992) [32] CSS Individuals in 1 tea estate (≥1) 1553 Mf NS
Khan et al. (1999) [NS] Study 1 [37] CSS Individuals in 1 tea estate (≥1) 821 Mf Hyd./Lymph.
Khan et al. (1999) [NS] Study 2 [40] CSS 2 communities: tea workers and non-tea workers (≥1) 1446 Mf NS
Khan et al. (1999) [NS] Study 3 [38] CSS 1 weaving community (≥1) 446 Mf -
Khan et al. (2004) [NS] [39] CSS Individuals in 1 tea estate (≥1) 656 Mf Hyd./Lymph.
Khan et al. (2015) (2012–2013) [41] CSS Individuals in 1 tea estate(infection ≥2, morbidity ≥18) 634 Mf Hyd./Lymph.
Medhi et al. (2006) (2002–2003) [47] CSS Households in 8 tea estates (≥1) 4016 Mf Hyd./Lymph.
Prakash et al. (1998) (1994) [51] CSS Households in 1 tea estate (≥1) 1105 Mf Hyd./Lymph.
Malaysia
Ahmad et al. (2014) [NS] [25] CSS Households/schools on 1 island (≥1) 298 Mf -
Cox-Singh et al. (1999) [NS] [31] CSS 2 districts (NS) 145 Mf, PCR -
Hakim et al. (1995) (1992) [34] FDT c 2 villages (≥6 months old) 499 Mf -
Jamail et al. (2005) (2001–2002) [35] FDE 7 districts(≥1) 2545 Mf, IgG4 -
Lim et al (2001) [NS] [46] FDE 5 villages and 2 schools (≥1) 1134 Mf, IgG4 -
Rahmah et al. (2003) [NS] [53] FDE 16 schools (7–12) 5138 IgG4 -
Rahmah et al. (2010) [NS] [54] FDE School children (6–10) 973 IgG4 -
Wan Omar et al. (2001) [NS] [62] FDE Migrant workers in palm oil estates (WA i) 630 Mf Lymph.
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Table 1. Cont.
Study (Publication Date) [Study Period] [Ref.] Study Design Sampling Population/Unit (Age of Participants) Sample Size
Diagnostic Method
Infection Morbidity
Thailand
Bhumiratana et al. (2004) (2002) [28] FDT Myanmar workers (WA i) 860 Mf, ICT, Og4C3 -
Bhumiratana et al. (2005) (1998–2001) [26] CSS Myanmars and Thais in multiple villages (≥1) 433 Mf, ICT, Og4C3 -
Bhumiratana et al. (1999) (1998) [27] FDE Multiple villages (≥1) 225 Mf, ICT Hyd.
Bhumiratana et al (2002) (1999) [29] CSS 1 village (≥1) 219 Mf, ICT Hyd.
Chansiri et al. (2002) (1997–2001) [30] CSS Migrant workers in 4 provinces (WA i) 1299 PCR -
Jiraamonnimit et al. (2009) (2005 to 2006] [36] LO d 3 provinces (≥7) 500 Mf, IgG4 Lymph.
Koyadun et al. (2003) (2001–2002) [43] FDT Myanmar migrants and Thais in 3 districts (≥15) 660 ICT -
Koyadun et al. (2005) (2003) [42] CSS Myanmar workers (≥10) 904 Mf -
Krairittichai et al. (2012) (2010) [44] RCS f Migrant workers at 1 hospital (WA i) 102,090 Mf -
Nuchprayoon et al. (2003) [NS] Study 1 [48] FDE Myanmar workers at 2 factories (WA i) 337 Mf, ICT, Og4C3 Hyd.
Nuchprayoon et al. (2003) [NS] Study 2 [49] CSS 2 villages (≥1) 433 Mf, Og4C3, IgG4 -
Nuchprayoon et al. (2001) [NS] [50] CSS 1 sub-district (≥1) 196 Mf, Og4C3, PCR -
Satimai et al. (2011) [NS] [57] CSS Myanmar migrants and Thais in 2 provinces (≥1) 1031 ICT, IgG4 -
Swaddiwudhipong et al. (1996) (1995) [58] CSS Myanmar workers and their families (≥1) 8377 Mf NS
Triteeraprapab et al. (1999) [NS] [61] CSS Myanmar workers in 6 industrial plants (WA i) 654 Mf -
Triteeraprapab et al. (2001) [NS] Study 1 [59] CSS 4 districts in 1 province (≥1) 2462 Mf -
Triteeraprapab et al. (2001) (1999) Study 2 [60] CSS Myanmar migrants in 1 community (≥2) 371 Mf, Og4C3, IgG4 -
a Field diagnostic test evaluation. b Cross-sectional survey. c Field Drug trial. d Longitudinal observational study. e Urine IgG4. f Retrospective cohort study. g Not stated. h
Hydrocoele/lymphoedema. i Working age.
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Table 2. Included grey literature.
Reports [Ref.] Year Sample Size Diagnostic Method
Infection Morbidity
Annual Reports
Myanmar Ministry of Health. National Program to Eliminate LF: Annual Reports [68–70]
2004 23,668 Mf -
2011 10,845 Mf -
2012 14,649 Mf Hyd./Lymph. c
World Health Organization Reports
WHO SEARO: Elimination of lymphatic filariasis in the Southeast Asia Region. Reports of the 1st, 7th,
8th, 9th, 10th Meeting of the Regional Program Review Group. [74–78]
2005
NS b
Mf
(ICT) a
Hyd./Lymph.
2010
2011
2012
2013
WHO Regional Office for Southeast Asia: Elimination of lymphatic filariasis in the Southeast Asia
Region. Reports of the 5th and 8th Meeting of the Regional Program Managers. [63,64]
2006
NS
Mf
(ICT) a
Hyd./Lymph.
2011
WHO Regional Office for Southeast Asia: Towards eliminating lymphatic filariasis: Progress in the
Southeast Asia Region (2001–2011). [5] 2013 NS Mf Hyd./Lymph.
WHO Regional Office for Southeast Asia: Regional Strategic Plan for Elimination of Lymphatic Filariasis
(2004–2007). [71] 2004 NS Mf Hyd./Lymph.
WHO Western Pacific Region: First Mekong-Plus Program Managers Workshop on Lymphatic Filariasis
and Other Helminthiasis. [66] 2009
Cambodia: 23,705
Lao PDR: 9286
Vietnam: 18,302
Mf/ICT Hyd./Lymph.
WHO Regional Office for the Western Pacific. Reports of the 13th and 14th Meeting of the Western
Pacific Regional Program Review Group on Neglected Tropical Diseases. [72,79]
2013
NS Mf/ICT Hyd./Lymph.
2014
WHO Malaysia Office. Country Cooperation Strategy 2009–2013. [67] 2010 NS Mf -
WHO: Meeting of the Neglected Tropical Disease Strategic and Technical Advisory Group’s Monitoring
and Evaluation Subgroup on Disease Specific Indicators. [80] 2014 NS Mf -
UNDP/World Bank/WHO/UNICEF. Research on rapid geographical assessment of Bancroftian
filariasis. [73] 1997 7000 ICT -
Non-Governmental Organization Reports
Family Health International 360 and USAID: End Neglected Tropical Diseases in Asia Final Report. [65] 2015
Cambodia: 18,809
Lao PDR:3472
Vietnam: NS
Mf/ICT Hyd./Lymph.
a ICT only used in one survey. b Not stated. c Hydrocoele/lymphoedema.
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4. Prevalence Results and Discussion by Country
4.1. Overview
This systematic review and meta-analysis assessed the prevalence estimates for LF infection and
morbidity in mainland Southeast Asia, Bangladesh and Northeast India. These estimates are important
for the successful implementation and evaluation of elimination programs. Data on the prevalence and
distribution of infection are needed to identify and prioritise regions for inclusion in MDA programs.
MDA rounds aim to interrupt LF transmission to prevent new infections, eventuating in LF elimination.
Prevalence data are then required following MDA rounds to evaluate their effectiveness and reassess
the need for further rounds. However, even after transmission has ceased, those with previous infection
may, or will have already developed chronic disease manifestations. National programs therefore
require data on the morbidity burden in order to implement alleviation programs.
Prevalence data from included studies and grey literature are summarised by country and region
in Tables S2–S3. Figure 2 illustrates the most recent distribution of LF compared to that at baseline
(pre-MDA).
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Exact prevalence estimates cannot be calculated because of the nature of available data. However,
we have attempted to estimate the current prevalence of infection and morbidity for each country
through assessment of pooled country estimates, grey literature and the quality of available data.
Given the varied sensitivity of detecti et s, e efined infection prevalence as low (Mf
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the national elimination program.
4.2. Bangladesh
4.2.1. Results
Grey literature indicates that bancr f fi i sis as endemic in 34 of the 64 districts of
Bangladesh during map ing betwe n 2002 a , it estimated 75.96 million of the country’s
148.77 million at risk [5,65,78]. Fifteen districts were considered low endemic with antigenaemia levels
greater than 1% but microfilaraemia less than <0.6% [65,80]. They did not undergo MDA and have
now passed two of three TAS, with the last to be completed in 2016 [65]. The remaining 19 districts
had initial microfilaraemia prevalences of 0.2–16% [80]. These districts completed MDA rounds in
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2014 and have now passed a TAS survey to determine whether MDA can be stopped, with a further
TAS planned for 2017 to 2018. National infection prevalence estimates decreased from 1% in 2004 to
0% in 2010 [5].
Three studies from 2011–2013 have assessed infection prevalence in the northern endemic states
of Nilphamari and Panchargarh [33,55,56]. They have found prevalences by Mf, ICT and IgG4 of
1.13%, 0.31–1.70% and 2.19%, respectively.
As of 2011, government surveys had identified 23,486 cases of lymphoedema (0.10%) and
65,320 (0.27%) cases of hydrocoele [76]. Two studies have assessed the morbidity prevalence in
Bangladesh [33,55]. A large household survey of 232,005 participants reported a lymphoedema
prevalence of 0.45%, whilst a smaller survey found a prevalence of lymphoedema and hydrocoele of
2.66% and 4.16% respectively
4.2.2. Discussion
Government data suggests W. bancrofti was historically widespread across Bangladesh with a
focus in the country’s west. Baseline infection prevalence appeared high to very high, consistent with
a previous review and a study of Bangladeshi migrants [15,62]. MDA in Bangladesh appears to have
been successful with both government data and recent studies demonstrating low to moderate levels
of ongoing infection. The country has now transitioned to post-MDA surveillance and will aim to
apply for elimination status after TAS in 2018.
Large-scale household surveys and government data suggest an overall low morbidity burden
but a high prevalence of lymphoedema and very high prevalence of hydrocoele in Nilphamari District.
As Bangladesh approaches LF elimination, resources should be shifted to further quantifying and
tackling the morbidity burden.
4.3. Cambodia
4.3.1. Results
Government mapping in 2004 reported 18 endemic districts in four northern and northeastern
provinces with 3.61% of the national population at risk (474 800) [5]. Government surveys reported a
pre-MDA prevalence of 0.38–2.75% in these provinces (mixed ICT and TBS) [65]. A 2000–2001 study in
these endemic provinces showed Mf and ICT prevalence ranging 0–1.13%, and 0–1.94%, respectively [45].
Five rounds of MDA were completed between 2005 and 2009. A post-MDA countrywide
serological study in 2012 found a prevalence by IgG4 of 6.60% in this north region and 1.19–1.65% in
the rest of the country [52]. All endemic districts passed required TAS by 2015 [65]. In 2016, Cambodia
was validated by the WHO as having eliminated LF as a public health problem [2].
In 2001, the government reported 58 cases of LF-related morbidity (40 lymphoedema and
18 hydrocoele) in Cambodia [66]. The highest prevalence was in Stung Treng (10), Takeo (10) and
Rattanakiri (9). A study from the same year found the prevalence of lymphoedema and hydrocoele in
endemic provinces ranged from 0 to 0.44% and 0 to 2.97% respectively [45].
4.3.2. Discussion
Government baseline mapping indicated W. bancrofti and B. malayi were endemic at low to
moderate levels in four provinces in northern Cambodia. Two representative studies and a prior
review confirmed these findings [14]. Cambodia completed post-MDA surveillance in 2015 and WHO
validated elimination of LF as a public health problem in 2016.
Whilst LF transmission has now ceased, an overall moderate combined morbidity burden remains
in Cambodia. Although the government reported only 58 cases of morbidity in 2001, a representative
survey from the same year found a low prevalence of lymphoedema (0.34%) and moderate prevalence of
hydrocoele (1.64%) across the four endemic provinces. When the study’s results are extrapolated using
1998 census population data [81], case estimates for lymphoedema and hydrocoele are 2800–17,382 and
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8474–27,461 in the four provinces, respectively. Now that MDA is complete, efforts in Cambodia need to
shift to assessing and alleviating the morbidity burden in the country.
4.4. Northeast India
4.4.1. Results
Filariasis is endemic in 250 districts across 20 states in India, with 617 million individuals at
risk [78]. Assam is considered the only endemic state in Northeast India [5].
Baseline government mapping from 2004 illustrates a line of endemic districts from the Bangladesh
to the Myanmar border with a prevalence of 0–5% [5].
Studies prior to the commencement of MDA in 2004 found a bancroftian Mf prevalence of
0.61–10.27% and 0.45–1.79% in tea-estate and non-tea-estate populations, respectively [32,37–40,51].
Sub-group meta-analysis showed a significantly higher Mf prevalence in populations living in
tea-estates (6.11%, 95%CI 3.49–9.41%) compared to those who did not (0.88%, 0.3–1.54) (p = 0.000).
A more recent study found persistent microfilaraemia of 7.41% in a tea-estate following six rounds of
MDA [41]. The government reports that the national infection prevalence has decreased from 1.24% in
2004 to 0.35% in 2011 [5].
The prevalence of lymphoedema and hydrocoele found in tea-estate populations was 0.12–0.72%
and 1.01–8.96%, respectively [32,37,39–41,51]. One study assessed morbidity in a non-tea-estate
community and found no clinical cases [40].
4.4.2. Discussion
Available data indicate that Assam is the only LF-endemic state in Northeast India. Baseline
mapping and studies demonstrated very high levels of W. bancrofti infection amongst those living in
tea-estates and a moderate prevalence in non-tea estate populations. Tea-estates are predominantly
composed of workers who migrated from states such as Bengal, Bihar, Odisha, Uttar Pradesh, Madhya
Pradesh, Tamil Nadu and Jharkhand as part of the British tea trade in the 19th and early 20th century.
Whilst national infection prevalence has progressively declined since the commencement of the MDA
program in 2004, a recent study found very high levels of persisting microfilaraemia in a tea-estate
following six rounds of MDA [41]. Reports of missed MDA rounds in seven districts in 2009, as well
as suboptimal drug coverage may account for the ongoing LF transmission in the region [63,74,75].
Further rounds of MDA with sufficient coverage and uptake are required.
Multiple representative studies have demonstrated an overall moderate burden of disease in
the tea-estate population of Assam with a low prevalence of lymphoedema but very high prevalence
of hydrocoele. Insufficient datawere available to assess the morbidity burden in the non-tea estate
population. In addition to ongoing MDA, programmatic efforts should focus on assessing the morbidity
burden in non-tea populations and implementing alleviation programs.
4.5. Lao PDR
4.5.1. Results
No studies on the prevalence of LF in Lao PDR were found.Grey literature indicates that
W. bancrofti is only endemic in the southern Attapeu and Sekong Provinces of Lao PDR with
137,000 individuals at risk [65,66,72,79]. Mapping of the Attapeu’s five districts in 2009 showed an
antigenaemia prevalence ranging 1.9–27.4% [65]. MDA commenced in Attapeu in one district in 2008
and was expanded to all five in 2009. Only one village in Sekong Province is endemic with a prevalence
of 6% [65]. Two rounds of focused MDA have been completed in this and surrounding villages.
Only one case of lymphoedema and no cases of hydrocoele have been reported in the country [66].
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4.5.2. Discussion
Government data from Lao PDR suggest that W. bancrofti is focussed in Attapeu province (along
the Cambodian border) and parts of the adjacent Sekong province. Infection prevalence was initially
considered low to moderate as noted by previous reviews [1,11,14,15]. However, further baseline
surveys in 2009 found very high levels of antigenaemia in Attapeu province. Since the commencement
of widespread MDA, infection prevalence appears to have decreased to low to moderate levels,
however no independent studies are available to validate government data.
Insufficient dataare available to assess the morbidity burden in Lao PDR. Given the infection
prevalence in Attapeu and morbidity burden in neighbouring Cambodia, numerous cases would be
expected. Further studies are urgently needed to validate government data and assess the morbidity
burden in Lao PDR.
4.6. Malaysia
4.6.1. Results
WHO reports indicate that 116 of the 994 implementation units (subdistricts and districts) are endemic
across Peninsular Malaysia, Sabah and Sarawak with 1.12 million people at risk [72,79]. Subperiodic
B. malayi accounts for the majority of cases, with 2% caused by W. bancrofti. Government data suggest
Mf prevalence had decreased from 1% to 0.2% in Peninsular Malaysia and 5.5% to 1.5% in Sabah and
Sarawak from the 1980s until the commencement of the National MDA Program in 2004 [66,67].
Pre-MDA studies of the local population in Peninsular Malaysia, Sabah and Sarawak found
a prevalence of B. malayi Mf of 0.26–23.85%, 20.69% and 0.90%, respectively [31,34,35,46,53].
Since 2004, Malaysia has completed five rounds of MDA in Peninsular Malaysia and seven rounds
in Sabah and Sarawak. As of 2014, only five IUs were still conducting MDA rounds with the remainder
commencing TAS [79]. More recent studies in Peninsular Malaysia have found a prevalence of Mf and
IgG4 of 0 and 2.16% respectively [25,54].
No data on the prevalence of LF-associated morbidity in the local Malaysian population
were found.
4.6.2. Discussion
Brugia malayi (and to a lesser extent W. bancrofti) was widely endemic across Peninsular Malaysia,
Sabah and Sarawak. Government surveys reported a low to moderate baseline infection prevalence.
Whilst pre-MDA studies showed greater levels of infection than government data, most were not
representative. These studies likely reflected the presence of highly-endemic foci in parts of Peninsular
Malaysia and Sabah, rather than a high baseline prevalence. More recent surveys suggest infection
levels are declining in Malaysia, although one study was conducted in a known low-endemic area [54].
Whilst recent government data are lacking, a 2016 xenomonitoring survey across five states in
Peninsular Malaysia and Sabah found no active transmission [82], suggesting a likely low level
of infection and supporting Malaysia’s progress toward LF elimination. Further studies are required to
assess current infection prevalence and the need for ongoing MDA.
Although there are no data on the morbidity prevalence in the local Malay population, a significant
burden of lymphoedema is expected given the previously highly endemic foci of B. malayi infection.
Studies assessing the morbidity burden are needed to fill this knowledge gap.
4.7. Myanmar
4.7.1. Results
Bancroftian filariasis is endemic in 45 of the 65 districts of Myanmar with 85.5% of the population
at risk [5]. No published prevalence studies on Myanmar were found. One study described in a WHO
report assessed filarial antigenaemia prevalence in 1997 [73]. One hundred individuals were tested by
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ICT from seventy randomly selected townships across 14 districts. The central and western dry zone
was highly endemic (20–30%) with the northern, eastern and southern areas less endemic or free from
filariasis. Most recent government microfilaraemia prevalence data for the western Sagaing, Magway,
Rakhine and Chin regions range from 0–65% [68–70]. Prevalence in Mandalay, Kayin and Yangon
regions ranges from 0–2% [68–70]. Mean national prevalence has reduced from 7.1% in 2001 to 2.7% in
2011 [5]. Myanmar commenced its MDA Program in 2001. As of 2014, the program had been scaled-up
to 22 of the 24 endemic districts.
One government survey assessed self-reported morbidity in 280 000 individuals in Sagaing region
in 2004 and identified 520 cases of lymphoedema (0.19%) and 827 cases of hydrocoele (0.59%) [68].
4.7.2. Discussion
Baseline surveys suggest that W. bancrofti were widely endemic in the low-lying parts of Myanmar
with over 85% of the population at risk. They suggested very high baseline levels of infection in the
central and western dry zones, consistent with that seen in Myanmar migrants in Thailand. Meanwhile,
the northern, eastern and southern areas were less endemic or free from filariasis. Government data
suggest declining levels of infection in Mandalay, Kayin and Yangon states since the commencement
of MDA, but very high rates of persisting infection in the western states of Sagaing, Magway, Rakhine
and Chin. As Myanmar continues to expand its MDA program, independent studies are required to
validate government prevalence data.
The only morbidity survey found low levels of self-reported lymphoedema and moderate levels of
hydrocoele in Sagaing region [68]. However, morbidity self-reporting questionnaires are not a sensitive
or specific indicator of clinical disease [45,83]. The significant morbidity found in Myanmar migrants in
Thailand suggests that the true morbidity prevalence is likely much higher. Representative prevalence
studies are required to elucidate the morbidity burden in Myanmar.
4.8. Thailand
4.8.1. Results
Baseline government mapping in 2001 found filariasis to be endemic in two foci in Thailand
with 160,000 individuals at risk [5]. Wuchereria bancrofti was present in five provinces along the
Thai-Myanmar border, whilst B. malayi was endemic along the southern Thai peninsula. Studies
in provinces along the Myanmar border between 1998 and 2003 found an infection prevalence of
1.01–10.20%, 13.3–26.42%, 21.89–36.79% and 53.93% by TBS, ICT, Og4C3 and IgG4, respectively [26,27,
29,49,50]. Meanwhile, studies conducted along the Thai peninsula between 2001 and 2006 reported
a prevalence of B. malayi infection of 0–2.00% and 8.00–23.67% by TBS and IgG4 [36,43,59].
The 11 studies which assessed infection in Myanmar migrants living in Thailand found a
prevalence of 0–5.83%, 0.2–13.57%, 4.0–23.98%, and 2.73–42.32% by TBS, ICT, Og4C3 and IgG4,
respectively [26,28,29,42,43,48,57,58,60,61].
Thailand commenced an elimination program in 2002. Mass drug administration was completed
in 2007 in all provinces except Narathiwatt, which extended rounds until 2011. Thailand commenced
the process of verifying LF elimination in 2012 after all areas passed TAS. National mean data suggest
infection prevalence has decreased from 0.77% in 2003 to 0.09% in 2010 [5]. No post-MDA prevalence
studies on the local population were identified.
Available studies have found the prevalence of lymphoedema and hydrocoele in the local
population in endemic areas was 1.2% and 0–8.15% [27,29,36]. Studies of Myanmar migrants found
a prevalence of hydrocoele of 8.62–16.13% [29,48]. As of 2011, the government had 200 identified cases
of lymphoedema [77].
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4.8.2. Discussion
Two highly endemic LF foci previously existed in Thailand. W. bancrofti was present along the
Thai-Myanmar border, whilst B. malayi was endemic along the southern Thai peninsula. Government
surveys suggest that LF transmission has ceased following MDA, but no studies have independently
verified this.
The influx of LF-infected Myanmar migrants into Thailand, combined with a documented ability
of Thai Culex quinquefasciatus mosquitoes to transmit the Myanmar strain of W. bancrofti has raised
concerns regarding the potential for re-introduction of transmission [84,85]. The Thai government
has acknowledged this and expanded its MDA program to include registered migrant workers from
Myanmar and Laos [57,86]. However, the considerable number of unregistered migrants still poses
a threat to elimination efforts.
Whilst the government had only identified 200 cases of lymphoedema in 2011, available studies
suggest a potentially moderate prevalence of lymphoedema and very high prevalence of hydrocoele
in previously endemic areas. However the representativeness of these surveys is uncertain, indicating
the need for further studies to establish the true disease burden in these areas.
4.9. Vietnam
4.9.1. Results
No peer-reviewed studies from Vietnam were identified. Government data suggest filariasis was
endemic in six of Vietnam’s eight regions during 1960–2000 [66]. However, by the start of the National
Elimination Program in 2003, only the Red River delta, north-central coast and central-southern
coast regions remained endemic despite no MDA [65,66]. Within these regions, 12 districts were
considered endemic and six selected for MDA with a total population at-risk of 675,000. Brugia malayi
predominates in the north with W. bancrofti in the south [65,66].
Baseline prevalence in endemic districts in 2002 ranged from 0 to 3.6% [65,66]. Vietnam completed
its MDA program in 2011 and passed TAS in all districts in 2015. It has subsequently applied to the
WHO for LF elimination confirmation [65].
A government clinical survey in 2002 in 77 districts reported 570 cases of limb morbidity and
47 cases of hydrocoele [66]. A later survey in 2012 identified 489 morbidity cases in five provinces [65].
4.9.2. Discussion
Filariasis was historically widespread in Vietnam with Brugia malayi predominating in the north
and W. bancrofti in the south. However by the commencement of the MDA Program, it had become
confined to the Red River delta, north-central coast and central-southern coast regions. These findings
are consistent with those found in prior reviews [14–16]. It has been suggested that the reduction
in infection prevalence prior to MDA was likely the result of improvements in housing and living
conditions, man-made ecological changes, the use of bed-nets and individual case treatment [16,65].
These changes appear to have resulted in low baseline infection prevalence levels by the start of the
MDA with the exception of Khanh Vinh and Ninh Hoa districts, where prevalence remained high.
Government data suggest that since MDA, LF transmission has now ceased, although no independent
studies have yet validated this.
Whilst government surveys suggest a relatively few cases of morbidity, the number of participants
surveyed is unknown, and therefore prevalence estimates cannot be made. Given filariasis was
historically widespread with some highly endemic foci, the true morbidity burden may be higher [16].
As Vietnam approaches LF elimination, studies are needed to validate government progress and assess
the morbidity burden in the country.
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4.10. Overall Prevalence Estimates for Mainland Southeast Asia
4.10.1. Meta-Analysis Results
A random effects meta-analysis of available infection and morbidity data was completed.
Figures 3–7 and Figures S1–S9 show the point estimates with 95% exact binomial confidence intervals
(95% CI) for each meta-analysis ordered by country and study date. Substantial heterogeneity between
surveys was demonstrated by I2 values, between 83.57% and 98.74%.Trop. Med. Infect. Dis. 2017, 2, 32  17 of 26 
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For microfilaraemia, 30 studies testing 133,747 individuals estimated a pooled prevalence of W.
bancrofti Mf of 1.77% (1.00–2.74%), B. malayi Mf of 0.36% (0.07–0.82%) and combined Mf of 2.64%
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(1.71–3.74%). For ICT antigenaemia, 10 studies testing 7237 individuals estimated a pooled prevalence
of 4.48% (1.97–7.87%). For IgG4 antibodies, 10 studies testing 14,339 individuals estimated a pooled
prevalence of 7.08% (3.63–11.54%).
For combined morbidity, 16 studies testing 256,591 individuals estimated a pooled prevalence
of 1.34% (0.81–1.97%). For hydrocoele, nine studies testing 4179 estimated a pooled prevalence of
3.84% (2.11–6.03%). For lymphoedema, nine studies testing 240,987 individuals estimated a pooled
prevalence of 0.49% (0.24–0.80%).Trop. Med. Infect. Dis. 2017, 2, 32  18 of 26 
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4.10.2. Discussion
Meta-analysis showed an overall high prevalence of infection (Mf: 2.64%, antigenaemia: 4.48%)
and moderate burden of morbidity (1.34%) in the region. However, pooled estimates and sub-group
analyses by country are biased by the significant differences in location, time, design, diagnosis
method, sampling unit and representativeness of the included studies, and should therefore be
interpreted with caution. Despite this, meta-analyses show a general decline in infection prevalence
with time and a higher prevalence of hydrocoele compared to lymphoedema across all countries
(overall hydrocoele:lymphoedema ratio of 7.84:1).
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In the context of pooled country estimates, grey literature and the quality of available data,
we conclude that Lao PDR, Myanmar and Northeast India demonstrate ongoing evidence of LF
transmission that will require multiple further rounds of MDA. Bangladesh, Malaysia, Thailand and
Vietnam appear close to having eliminated LF, whilst Cambodia has already achieved elimination
status. We estimated that the burden of morbidity is likely high in Thailand, moderate in Cambodia,
Myanmar, and Northeast India, and low in Bangladesh. There was insufficient evidence to accurately
estimate the disease burden in Lao PDR, Malaysia or Vietnam.
These results indicate that whilst considerable progress toward LF elimination has been made,
there remains a significant filariasis burden in the region. The results will assist policy makers to
advocate and budget for future MDA and morbidity control programs.Trop. Med. Infect. Dis. 2017, 2, 32  19 of 26 
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4.11. Limitations
This systematic review was hindered by limitations at the study and review level. The overall
quality of primary studies was suboptimal. Only 18% of studies used fully representative sampling
methods and consensus data collection methods. Some of the studies were out-dated because one or
more MDA rounds had occurred since data collection. The quality of grey literature further hindered
data analysis. Available reports frequently omitted sample sizes or gave prevalence data in percentage
ranges, making further analysis difficult.The uncertain methodology of government surveys further
complicated grey literature assessment. Whilst national programs follow the WHO guidelines, there is
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often considerable variation in sampling and data collection practices in the field [22]. No published
studies were available from Lao PDR, Myanmar or Vietnam to compare with government data.
Incomplete literature retrieval led to limitations at the review level. Original copies of government
annual reports were obtained only from Myanmar, although use of WHO reports alleviated this
deficiency to some extent. Retrieval of these data would provide a more complete picture of filariasis
prevalence in these countries.Trop. Med. Infect. Dis. 2017, 2, 32  20 of 26 
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The lack of representative and recent studies in many of the countries placed reliance on
government sources for current prevalence data. Whilst sufficient information on infection was
available to produce country estimates, data on the morbidity burden are notably lacking. This
indicates the substantial need for further studies, with a particular focus on morbidity, to more
accurately assess the current LF prevalence in the region.
It is important to note that the findings and conclusions in this paper are based solely on
published prevalence data. It is therefore possible that they may not truly reflect the actual situation in
these countries.
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5. Conclusions 
Considerable progress has been made toward the LF elimination in mainland Southeast Asia, 
Bangladesh and Northeast India. Five of the eight countries reviewed are close to eliminating, or have 
eliminated, LF infection. The remaining three countries will require increasing support if they are to 
achieve LF elimination by 2020. The significant morbidity burden in the region requires increasing 
and urgent attention. Further studies are needed to more accurately assess the morbidity prevalence 
and implement desperately needed alleviation programs. 
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Percentage estimates of Og4C3 antigena mia pr valence by country and year; Figure S4: Percentage estimates
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prevalence in Northeast India; Figure S6: Percentage estimates of combined microfilaraemia prevalence in
Thailand; Figure S7: Percentage estimates of ICT antigenaemia prevalence in Thailand; Figure S8: Percentage
Trop. Med. Infect. Dis. 2017, 2, 32 22 of 26
estimates of hydrocoele prevalence in Thailand; Figure S9: Percentage estimates of combined morbidity prevalence
in Thailand. Figure S10: PRISMA checklist.
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